PURPOSE: Long-term epilepsy associated tumors (LEATs) are a frequent cause of drug-resistant partial epilepsy. A reliable tumor diagnosis has an important impact on therapeutic strategies and prognosis in patients with epilepsy, but often is difficult by magnetic resonance imaging (MRI) only. Herein we analyzed a large LEAT cohort investigated by 18fluoroethyl-L-tyrosine-positron emission tomography (FET-PET). METHODS: Thirty-six patients with chronic partial epilepsy and a LEAT-suspect MRI lesion were analyzed by FET-PET using visual inspection and quantitative analysis of standard uptake values (SUV). PET results were correlated with clinical and histopathologic data. RESULTS: FET-PET study was positive in 22 of 36 analyzed lesions and in 14 of 22 histologically verified LEAT lesions. The precise World Health Organization (WHO) tumoral entity was not predicted by FET-PET. Notably, FET uptake correlated strikingly with age at epilepsy onset (p = 0.001). Further correlations were seen for age at surgery (p = 0.007) and gadolinium-contrast enhancement on MRI (p < 0.05). DISCUSSION: FET-PET is a helpful tool for LEAT diagnosis, particularly when MRI readings are ambiguous. FET uptake, which is likely mediated by the l-amino acid transporter (LAT) family, might indicate a principally important biologic property of certain LEATs, since LAT molecules also are involved in cell growth regulation. Wiley Periodicals, Inc.
PURPOSE: Long-term epilepsy associated tumors (LEATs) are a frequent cause of drug-resistant partial epilepsy. A reliable tumor diagnosis has an important impact on therapeutic strategies and prognosis in patients with epilepsy, but often is difficult by magnetic resonance imaging (MRI) only. Herein we analyzed a large LEAT cohort investigated by 18fluoroethyl-L-tyrosine-positron emission tomography (FET-PET). METHODS: Thirty-six patients with chronic partial epilepsy and a LEAT-suspect MRI lesion were analyzed by FET-PET using visual inspection and quantitative analysis of standard uptake values (SUV). PET results were correlated with clinical and histopathologic data. RESULTS: FET-PET study was positive in 22 of 36 analyzed lesions and in 14 of 22 histologically verified LEAT lesions. The precise World Health Organization (WHO) tumoral entity was not predicted by FET-PET. Notably, FET uptake correlated strikingly with age at epilepsy onset (p = 0.001). Further correlations were seen for age at surgery (p = 0.007) and gadolinium-contrast enhancement on MRI (p < 0.05). DISCUSSION: FET-PET is a helpful tool for LEAT diagnosis, particularly when MRI readings are ambiguous. FET uptake, which is likely mediated by the l-amino acid transporter (LAT) family, might indicate a principally important biologic property of certain LEATs, since LAT molecules also are involved in cell growth regulation. Wiley Periodicals, Inc.
Authors: Markus Hutterer; Martha Nowosielski; Daniel Putzer; Christian la Fougère; Irene J Virgolini; Andreas H Jacobs; Günther Stockhammer Journal: Neuro Oncol Date: 2013-06-19 Impact factor: 12.300
Authors: Martin Misch; Andreas Guggemos; Pablo Hernáiz Driever; Arend Koch; Frederik Grosse; Ingo G Steffen; Michail Plotkin; Ulrich-Wilhelm Thomale Journal: Childs Nerv Syst Date: 2014-09-18 Impact factor: 1.475
Authors: Bálint Alkonyi; Sandeep Mittal; Ian Zitron; Diane C Chugani; William J Kupsky; Otto Muzik; Harry T Chugani; Sandeep Sood; Csaba Juhász Journal: J Neurooncol Date: 2011-11-03 Impact factor: 4.130
Authors: Jack M Webster; Christine A Morton; Bruce F Johnson; Hua Yang; Michael J Rishel; Brian D Lee; Qing Miao; Chittari Pabba; Donald T Yapp; Paul Schaffer Journal: J Nucl Med Date: 2014-02-27 Impact factor: 10.057
Authors: Markus Hutterer; Martha Nowosielski; Daniel Putzer; Nathalie L Jansen; Marcel Seiz; Michael Schocke; Mark McCoy; Georg Göbel; Christian la Fougère; Irene J Virgolini; Eugen Trinka; Andreas H Jacobs; Günther Stockhammer Journal: Neuro Oncol Date: 2013-01-17 Impact factor: 12.300
Authors: Pablo Bascuñana; Mirjam Brackhan; Ina Leiter; Heike Keller; Ina Jahreis; Tobias L Ross; Frank M Bengel; Marion Bankstahl; Jens P Bankstahl Journal: J Cereb Blood Flow Metab Date: 2018-10-30 Impact factor: 6.200